Genentech and Roche have voluntarily recalled their ophthalmology biobetter, Susvimo, an ocular implant for ranibizumab injection, in the United States for a possible leakage issue.
Genentech, a member of the Roche group, announced a voluntariy recall of Susvimo, an ocular implant for ranibizumab injection that is a biobetter for Lucentis (ranibizumab), in the United States, according to a report from Ophthalmology Times.
“The voluntary recall is based on recent testing of our commercial supply in which Susvimo implants were exposed to repeated puncturing with a needle…The results showed that some implants did not perform to our standards…. We deeply regret any disruption that this may cause to people with wet AMD and the retinal community,” Genentech explained in a statement.
Biobetters are a class of follow-on biologic products that are intentionally altered to improve clinical effects, allow for more time in between doses, or enhance tolerability.
Susvimo is used as an insertion tool for the treatment of people with neovascular age-related macular degeneration (wet AMD). Susvimo offers benefits over Lucentis in that Susvimo contains a reservoir of ranibizumab that can last for 6 months, enabling patients to require less trips to the doctor’s office over the course of a year, thereby increasing medication adherence and making it easier for patients to manage wet AMD. By contrast, regular injections of Lucentis or a ranibizumab biosimilar are required as often as once a month.
The product was approved by the FDA in October 2021. Following the approval, 2 ranibizumab biosimilars (Byooviz and Cimerli) referencing the originator (Lucentis) have enter the market, including one with an interchangeability designation (Cimerli). The approval of Susvimo raised concerns for biosimilar manufacturers, as many patients may be persuaded to switch from the originator to the ocular implant before patient have has the opportunity to try a biosimilar that is priced lower than both products.
According to Roche’s most recent earnings report, Susvimo accumulated about $3 million in revenue over the last quarter. Additionally, Lucentis generated about $800 million in quarterly revenues, a 25% drop from the previous quarter, which the company attributed to the market introduction of Byooviz (ranibizumab-runa) at the beginning of the third quarter of 2022.
Genentech said that it has notified the FDA and is working with the agency on the recall process. It also claimed that it has taken “immediate steps to inform other health authorities, healthcare professionals, clinical trial investigators, and patient organizations” and it will offer support and guidance to help maintain clinical outcomes for patients. The company recommended that health care providers discuss the continuation of treatment with their patients who are treated with Susvimo and it said that it will be closely monitoring patients in line with FDA-approved label and clinical trial protocols.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.